China Resources Pharmaceutical Delivers Solid Interim Results

Press time:2017-08-25From:CR Pharma [ Font:BigMediumSmall]

(Hong Kong, 24 August 2017) – China Resources Pharmaceutical Group Limited (CR Pharma) (stock code: 3320), announced its interim results for the six months ended 30 June 2017 (“Reporting Period”).   

During the Reporting Period, CR Pharma recorded total revenue of approximately HK$82,737.6 million, representing an increase of 9.4% year-on-year (an increase of 15% in RMB terms); gross profit for the period amounted to approximately HK$12,528.0 million, representing an increase of 6.6% year-on-year (12.1% in RMB terms). Gross profit margin was 15.1%, down only by a slight 0.4 percentage points. Profit attributable to owners of CR Pharma was approximately HK$1,810.4 million, representing an increase of 10.7% year-on-year (16.3% in RMB terms). Should nonrecurring profit and loss be excluded, the growth in profit attributable to owners of CR Pharma for the period would be even more considerable. During the Reporting Period, basic earnings per share were HK$0.29. 

As at 30 June 2017, Revenue of its three major business segments, namely pharmaceutical manufacturing, pharmaceutical distribution and pharmaceutical retail, accounted for 13.9%, 83.5% and 2.6% of CR Pharma’s total revenue, respectively. Attributable mainly to product mix optimization and continuous improvement of the manufacturing process, Pharma manufacturing business achieved stable revenue growth and better profitability. CR Pharma started strategic cooperation on multi-front with partners. A number of major projects were complete and applications for those cooperated with National Natural Science Foundation of China were made. In addition, certain products of clinical and market values were introduced. The coverage of pharma distribution business network kept growing. Pharma distribution business entered into four provinces, namely Jiangxi, Hainan, Qinghai as well as Xinjiang, thus accomplishing a pharmaceutical distribution network that to date covers 27 provinces, municipalities and autonomous regions. Pharma retail business gradually strengthens its competitiveness through integration of brand, operation management, data systems and other aspects of pharmaceutical retail resources, as well as development of innovative business.    

Looking ahead, CR Pharma will continue to implement its six key business expansion strategies. By relying on its own advantages and following the direction of the policies and the market demand, CR Pharma will speed up the development through strategic mergers and acquisitions and international collaboration. It will improve its intrinsic development potential through optimizing product mix and business model, optimizing the research and development and innovation system and deepening synergy effects so as to achieve the long-term stable and sustainable development in the pharmaceutical manufacturing, distribution and retail segments and continue to reinforce and elevate CR Pharma’s leading position in the pharmaceutical industry in China. 

Prev | Next
网上赚钱项目排行 织金县| 兖州市| 寿宁县| 乃东县| 永顺县| 湖州市| 吴堡县| 应城市| 平塘县| 安顺市| 南充市| 凉山| 三亚市| 陆河县| 江华| 象山县| 望城县| 湘潭县| 柯坪县| 汤阴县| 抚松县| 金溪县| 汾阳市| 东莞市| 土默特右旗| 铜陵市| 伊宁市| 古浪县| 聂拉木县| 伊通| 新河县| 简阳市| 田东县| 西藏| 丹巴县| 广南县| 广河县| 海南省| 原平市| 厦门市| 闽清县| 上蔡县| 葵青区| 阳泉市| 清镇市| 深水埗区| 岳西县| 白山市| 宝应县| 昌吉市| 鹤峰县| 阿克| 通州市| 横峰县| 克山县| 田东县| 晋州市| 通山县| 普定县| 石狮市| 鄂托克前旗| 大丰市| 禹城市| 天长市| 九龙县| 嘉义县| 六盘水市| 襄汾县| 临高县| 新疆| 永嘉县| 井冈山市| 辉县市| 荣成市| 西和县| 尤溪县| 荔浦县| 临洮县| 南召县| 定陶县| 彭山县| 大荔县| 绥芬河市| 长岭县| 曲松县| 威宁| 盘锦市| 梓潼县| 财经| 连山| 陵水| 怀化市| 林口县| 黄山市| 洛宁县| 三亚市| 安陆市| 青川县| 蚌埠市| 庆城县| 朝阳区| 林西县| 廉江市| 乐至县| 吉隆县| 阿拉善盟| 乐清市| 甘德县| 迭部县| 海盐县| 聂拉木县| 宁都县| 鹤岗市| 双桥区| 萍乡市| 丽江市| 溆浦县| 深泽县| 滦平县| 堆龙德庆县| 手游| 栾城县| 囊谦县| 上思县| 额尔古纳市| 乌什县| 红安县| 荆州市| 冷水江市| 安塞县| 万源市| 子洲县| 措勤县| 苍梧县| 郸城县| 丹巴县| 鄂温|